Variable | Enrollees (%) | Treatment changes (%) | Follow-up/months | Rates/ 1000 | cHazard Ratio* | 95% CI | p-value∞ | aHazard Ratio# | 95% CI | p-value |
---|---|---|---|---|---|---|---|---|---|---|
YEAR | N = 3933 | N = 960 | ||||||||
2008 | 836 (21.3) | 234 (24.4) | 30,937.9 | 7.56 | – | – | – | – | – | – |
2009 | 810 (20.6) | 240 (25.0) | 21,883.7 | 10.97 | 1.46 | 1.21 to 1.75 | <0.0001 | 1.54 | 1.27 to 1.88 | <0.0001 |
2010 | 804 (20.4) | 280 (29.2) | 15,640.9 | 17.90 | 2.75 | 2.27 to 3.33 | <0.0001 | 4.15 | 3.34 to 5.14 | <0.0001 |
2011 | 753 (19.1) | 171 (17.8) | 9137.9 | 18.73 | 2.99 | 2.39 to 3.73 | <0.0001 | 11.55 | 8.70 to 15.35 | <0.0001 |
2012 | 730 (18.6) | 35 (3.6) | 3736.3 | 9.37 | 1.33 | 0.91 to 1.94 | 0.139 | 1.43 | 0.89 to 2.33 | 0.153 |
HAART TYPE | ||||||||||
AZT/3TC/EFV | 1468 (37.3) | 117 (12.2) | 33,335.5 | 3.51 | – | – | – | – | – | – |
AZT/3TC/NVP | 898 (22.8) | 90 (9.4) | 23,238.4 | 3.87 | 1.10 | 0.83 to 1.44 | 0.510 | 1.14 | 0.85 to 1.53 | 0.381 |
d4T/3TC/EFV | 718 (18.3) | 461 (48.0) | 12,751.1 | 36.15 | 10.80 | 8.80 to 13.35 | <0.0001 | 12.05 | 9.58 to 15.16 | <0.0001 |
d4T/3TC/NVP | 399 (10.1) | 270 (28.1) | 7705.4 | 35.04 | 10.42 | 8.38 to 12.96 | <0.0001 | 12.03 | 9.27 to 15.61 | <0.0001 |
TDF/3TC/EFV | 314 (8.0) | 5 (0.5) | 2528.6 | 1.98 | 0.59 | 0.24 to 1.45 | 0.252 | 0.22 | 0.09 to 0.56 | 0.0013 |
TDF/3TC/NVP | 71 (1.8) | 3 (0.3) | 637.5 | 4.71 | 1.43 | 0.45 to 4.50 | 0.542 | 0.58 | 0.18 to 1.85 | 0.358 |
OTHERS | 65 (1.7) | 14 (1.5) | 1130.3 | 12.39 | 3.69 | 2.19 to 6.42 | <0.0001 | 2.99 | 1.71 to 5.23 | 0.0001 |
GENDER | ||||||||||
Male | 1373 (34.9) | 282 (29.4) | 28,625.7 | 9.85 | – | – | – | – | – | – |
Female | 2560 (65.1) | 678 (70.6) | 52,701.0 | 12.87 | 1.31 | 1.14 to 1.50 | 0.0002 | 1.19 | 1.01 to 1.39 | 0.031 |
AGE GROUP | ||||||||||
< 25 | 199 (5.1) | 44 (4.6) | 3573.7 | 12.31 | – | – | – | – | – | – |
25–34 | 1112 (28.3) | 277 (28.8) | 24,080.0 | 11.50 | 0.95 | 0.69 to 1.31 | 0.755 | 1.01 | 0.73 to 1.40 | 0.939 |
35–44 | 1251 (31.8) | 307 (32.0) | 25,904.0 | 11.85 | 0.97 | 0.71 to 1.33 | 0.864 | 1.03 | 0.75 to 1.42 | 0.871 |
45–54 | 709 (18.0) | 169 (17.6) | 14,081.4 | 12.00 | 0.99 | 0.71 to 1.37 | 0.945 | 1.09 | 0.78 to 1.54 | 0.605 |
55–64 | 192 (4.8) | 44 (4.6) | 3633.0 | 12.11 | 0.99 | 0.65 to 1.51 | 0.968 | 0.93 | 0.60 to 1.42 | 0.721 |
≥ 65 | 470 (12.0) | 119 (12.4) | 10,054.6 | 11.84 | 0.98 | 0.69 to 1.38 | 0.903 | 0.94 | 0.66 to 1.33 | 0.706 |
WHO Stage | ||||||||||
I | 402 (10.2) | 37 (3.9) | 5840.4 | 6.34 | – | – | – | – | – | – |
II | 662 (16.8) | 68 (7.1) | 14,568.5 | 4.67 | 0.76 | 0.51 to 1.14 | 0.189 | 0.87 | 0.71 to 1.36 | 0.294 |
II | 1042 (26.5) | 187 (19.4) | 15,465.5 | 12.09 | 1.93 | 1.36 to 2.74 | 0.0003 | 2.33 | 1.44 to 3.02 | 0.007 |
IV | 491 (12.5) | 115 (12.0) | 7901.6 | 14.55 | 2.31 | 1.60 to 3.35 | <0.0001 | 2.73 | 1.49 to 4.02 | <0.0001 |
Missing | 1336 (34.0) | 553 (57.6) | 37,550.7 | 14.73 | 2.38 | 1.71 to 3.33 | <0.0001 | 2.83 | 1.82 to 3.88 | <0.0001 |